CymaBay Therapeutics Inc.

3.74-0.4200-10.10%Vol 790.44K1Y Perf 8.05%
Aug 11th, 2022 16:00 DELAYED
BID3.74 ASK3.80
Open4.20 Previous Close4.16
Pre-Market- After-Market3.89
 - -  0.15 4.01%
Target Price
10.25 
Analyst Rating
Strong Buy 1.00
Potential %
174.06 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★ —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
67.43 
Earnings Rating
Strong Buy
Market Cap316.69M 
Earnings Date
11th Aug 2022
Alpha0.01 Standard Deviation0.25
Beta0.69 

Today's Price Range

3.734.23

52W Range

1.674.74

5 Year PE Ratio Range

-7.90-5.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-12.00%
1 Month
10.98%
3 Months
110.11%
6 Months
18.35%
1 Year
8.05%
3 Years
-35.96%
5 Years
-43.07%
10 Years
-

TickerPriceChg.Chg.%
CBAY3.74-0.4200-10.10
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.31-0.32-3.23
Q04 2021-0.36-0.345.56
Q03 2021-0.29-0.33-13.79
Q02 2021-0.27-0.34-25.93
Q01 2021-0.24-0.25-4.17
Q04 2020-0.20-0.23-15.00
Q03 2020-0.17-0.170.00
Q02 2020-0.23-0.1630.43
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.306.25Positive
9/2022 QR-0.316.06Positive
12/2022 FY-1.231.60Positive
12/2023 FY-1.29-1.57Negative
Next Report Date-
Estimated EPS Next Report-0.30
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume790.44K
Shares Outstanding84.68K
Shares Float71.58M
Trades Count6.03K
Dollar Volume3.09M
Avg. Volume690.07K
Avg. Weekly Volume633.96K
Avg. Monthly Volume657.68K
Avg. Quarterly Volume778.56K

CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock closed at 3.74 per share at the end of the most recent trading day (a -10.1% change compared to the prior day closing price) with a volume of 790.44K shares and market capitalization of 316.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. CymaBay Therapeutics Inc. CEO is Sujal Shah.

The one-year performance of CymaBay Therapeutics Inc. stock is 8.05%, while year-to-date (YTD) performance is 10.65%. CBAY stock has a five-year performance of -43.07%. Its 52-week range is between 1.6701 and 4.74, which gives CBAY stock a 52-week price range ratio of 67.43%

CymaBay Therapeutics Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 2.67, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -60.79%, a ROC of -59.70% and a ROE of -87.94%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CymaBay Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. CymaBay Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for CymaBay Therapeutics Inc. is Strong Buy (1), with a target price of $10.25, which is +174.06% compared to the current price. The earnings rating for CymaBay Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CymaBay Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CymaBay Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.57, ATR14 : 0.27, CCI20 : 70.79, Chaikin Money Flow : 0.17, MACD : 0.30, Money Flow Index : 63.80, ROC : 14.72, RSI : 59.27, STOCH (14,3) : 56.42, STOCH RSI : 0.00, UO : 56.06, Williams %R : -43.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CymaBay Therapeutics Inc. in the last 12-months were: Dennis D. Kim (Buy at a value of $60 800), Sujal Shah (Buy at a value of $100 037)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (100.00 %)
8 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

CEO: Sujal Shah

Telephone: +1 510 293-8800

Address: 7575 Gateway Boulevard, Newark 94560, CA, US

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

50%50%

Bearish Bullish

53%47%

TipRanks News for CBAY

Mon, 21 Mar 2022 14:35 GMT CymaBay Therapeutics (CBAY) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Fri, 18 Mar 2022 10:26 GMT CymaBay Therapeutics (CBAY) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits